Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HLF
REST API REST API
Homo sapiens
HLF is differentially expressed in 293 experiments: 155 organism parts: liver, bone marrow, ... (153 more);, 211 disease states: normal, control, ... (209 more);, 80 cell types 296 cell lines 32 compound treatments and 74 other conditions.
Synonyms MGC33822
Orthologs F6URF6_CIOIN (Ciona intestinalis)   F1NBU3_CHICK (Gallus gallus)   E1BFR1_BOVIN (Bos taurus)   Hlf (Mus musculus)   hlfb (Danio rerio)   LOC690286 (Rattus norvegicus)   Pdp1 (Drosophila melanogaster)   hlf (Xenopus laevis)   HLF (Canis familiaris)   (Compare orthologs)
InterPro Term bZIP_2, TF_bZIP
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, double-stranded DNA binding, transcription from RNA polymerase II promoter, sequence-specific DNA binding, protein dimerization activity, multicellular organismal development, rhythmic process, nucleus, sequence-specific DNA binding transcription factor activity
UniProt Accession Q6FHS9, Q16534, A8K1X8
Search EB-eye ENSG00000108924
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (29 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-5823, E-GEOD-20081
SW480
1
3
E-MEXP-1014, E-GEOD-18005, E-GEOD-2509, E-MTAB-37
BT-474
2
E-GEOD-5823, E-GEOD-3529
HCC1143
2
E-MTAB-62, E-MTAB-37
HCC2157
2
E-MTAB-37, E-MTAB-62
LNCaP
2
E-GEOD-14990, E-GEOD-14464
290 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-360, ... (42 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-GEOD-6740, E-MTAB-25, E-AFMX-5
2
E-TABM-130, E-TABM-145
fibroblast
2
E-GEOD-3204, E-GEOD-3920
macrophage
1
2
E-GEOD-3982, E-GEOD-8286, E-GEOD-360
basal cell
1
E-GEOD-3998
CD34+ hematopoietic stem cell
1
E-MEXP-1546
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (72 experiments)

Factor Value U/D Experiments
control
4
E-GEOD-21912, E-GEOD-20295, E-GEOD-16363, E-GEOD-20168
prostate carcinoma
1
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62, E-TABM-26
lung adenocarcinoma
1
3
E-GEOD-2514, E-MEXP-231, E-MTAB-62, E-MTAB-37
chronic myelogenous leukemia
2
E-GEOD-5550, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
prostate cancer
2
E-GEOD-6919, E-MTAB-62
205 more value(s).


Compound treatment

studied in E-MEXP-2449, E-GEOD-4668, E-GEOD-6907, E-GEOD-5824, E-GEOD-3720, ... (20 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-GEOD-412, E-GEOD-7307, E-GEOD-1740, E-GEOD-6907, ... (7 experiments)
glutamine
2
E-MEXP-941, E-MEXP-1335
PTTG
1
1
E-MEXP-2449
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
ZMYM2/FGFR1
1
1
E-GEOD-15811
interferon-gamma + lipopolysaccharide
1
E-GEOD-7307
26 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-994, E-GEOD-5372, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1638, E-GEOD-2666, E-GEOD-4667, ... (8 experiments)

Disease staging
studied in E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, E-MEXP-2280, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-6431, E-MEXP-2340

Genotype
studied in E-TABM-1029, E-GEOD-1045, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-2117, E-TABM-263, E-TABM-127, E-MEXP-1446, E-MEXP-1273, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (32 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-TABM-130, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-MEXP-1412 ... (5 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-22541, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.254 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM